Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][4] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise a total of no more than 2 billion yuan, with the funds primarily directed towards the development of an AI-driven collagen database and product development platform [2][3] - The introduction of Yangshengtang as a strategic investor is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [2] Group 2 - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, primarily utilizing methods such as private placements and convertible bonds, with Jinbo Bio's project being a significant breakthrough in the past two years [4] - The successful implementation of Jinbo Bio's stock issuance is anticipated to enhance overall market attention towards companies on the Beijing Stock Exchange, attracting various long-term funds and improving market liquidity and investor returns [5] - This project is expected to provide replicable and referable practical experience for future refinancing efforts on the Beijing Stock Exchange, aligning with its core mission to serve innovative small and medium-sized enterprises [5]

Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][3] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise no more than 2 billion yuan, with the funds primarily directed towards the development of an AI research platform [1][2] - The strategic investor, Yangshengtang, is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [1] Group 2 - The funds raised will focus on the "Humanized Collagen FAST Database and Product Development Platform Project," which utilizes the company's self-developed "AI Collagen Brain System" technology to enhance efficiency in the development of humanized collagen [2] - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, with the current focus on targeted convertible bonds and stock issuance, as evidenced by Jinbo Bio's successful registration [3] - The successful implementation of Jinbo Bio's stock issuance is expected to increase overall market attention on companies listed on the Beijing Stock Exchange, attracting various long-term funds and enhancing market liquidity [4]

Group 1: Quantum Technology - The report highlights significant advancements in quantum error correction technology, with Zhejiang University and Tsinghua University demonstrating low-overhead quantum error correction codes, effectively reducing logical error rates below physical error rates [4][5] - Horizon Quantum Computing has formed a strategic partnership with Alice&Bob to accelerate the development of fault-tolerant quantum computing, integrating their software and hardware capabilities [5] - GuoDun Quantum plans to sign a technology licensing contract with the University of Science and Technology of China, involving quantum random number generators and superconducting quantum computing control systems [6][7] Group 2: Biomanufacturing - The Chinese Academy of Sciences has achieved a breakthrough in synthesizing L-arginine using methanol as the sole carbon source, marking a shift towards non-grain-based production methods [8][9] - The Shenzhen Advanced Institute has developed the MARS intelligent system, which integrates multiple AI agents and robots to significantly shorten the new material development cycle from four months to four hours [9][10] - Jinbo Biological has registered a 2 billion yuan private placement to enhance its humanized collagen protein FAST database project, aiming to improve research and development efficiency [11] Group 3: Hydrogen Energy and Nuclear Fusion - The Baowu Clean Energy green hydrogen industrial park project, with a total investment of 11.09 billion yuan, has been launched in Guangdong, establishing a new model for offshore wind power direct hydrogen production [12][13] - A Chinese consortium has signed a significant contract for the ITER edge local model power supply system, marking a major step in China's contribution to global fusion energy projects [15] - Zhejiang Fu Nuclear Power will participate in the development of core components for the China Fusion Engineering Demonstration Reactor (CFEDR), focusing on ultra-high heat load components [16][17] Group 4: Brain-Computer Interfaces - Neuralink has successfully implemented OTA wireless upgrades for its invasive brain-computer interface, allowing for performance optimization without the need for additional surgeries [18][19] - This advancement addresses the traditional limitations of invasive devices, reducing clinical maintenance risks and costs while enhancing the adaptability of the technology [20] Group 5: Embodied Intelligence - World Labs, founded by Fei-Fei Li, has partnered with Guanglun Intelligent to create an evaluation system for embodied intelligence, addressing high verification costs and discrepancies between simulation and reality [21][22] - The Marble model developed by World Labs generates high-fidelity 3D environments from various inputs, solving traditional model issues but lacking physical interaction capabilities [22][23] Group 6: Future Industry Catalysts - The report outlines key catalytic events for 2026 across six future industries, including significant conferences and technological milestones that investors should monitor [28][29]

证券研究报告 全球跨境电商前景可观，北交所拟上市公司千岸科技、尚睿科技发展自主品牌 ——北交所消费服务产业跟踪第四十九期（20260125） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 联系人 2013-2024 年中国跨境电商市场规模 CAGR 约为 17%，跨境出口电商具备优势。根 据 PrecedenceRESEARCH 数据，2025 年全球跨境电商市场规模为 5512.3 亿美元， 预计从 2026 年的 6363.4 亿美元增至 2034 年的约 2 万亿美元，复合年增长率高达 15.44%。随着我国跨境电商市场规模的快速发展，跨境电商新业态对传统外贸高质 量发展的促进作用越发明显，根据网经社电子商务研究中心的数据，2024 年中国跨 境电商市场规模为 17.66 万亿元，2013-2024 年复合增速约为 17%，其中跨境出口 电商占据了我国跨境电商市场的大部分市场份额。根据 Cognitive Market Research 数据，北美跨境电商市场在全球跨境电商市场占据主导地位，2025 年市场销售收入 达 1.63 万亿美元，预计 2025-2033 年的复合年增长率为 17.9 ...

北交所策略专题报告 2026 年 01 月 25 日 北交所主题基金 2025 年成绩单平均 55.53%，把脉 2026 年结构性机会 ——北交所策略专题报告 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 公布 2025Q4 季报，11 家主题基金 2025 年收益率均值达 55.53% 从公募机构在北交所配置家数来看，2024 年末共计 29 家公募机构配置北交所股 票，同比增长 31.82%，2025 年末公募基金重仓北交所企业的数量分别为 41 家， 同比 2024 年末增长 41.38%。从公募机构在北交所重仓配置金额角度来看，2025 年末公募机构在北交所重仓配置金额 90.50 亿元，重仓配置占比达 0.12%。其中 2025 年单季度末公募机构在北交所重仓配置金额分别为 67.43 亿元、98.92 亿元、 103.07 亿元、90.50 亿元，重仓配置占比达 0.11%、0.17%、0.14%、0.12%。从被 动指数基金规模角度来看，2025 年北证 50 指数基金规模高增长。2022-2026 年 北证 50 指数基金规模 ...

Group 1 - The report highlights the introduction of the "Interim Measures for the Recycling and Comprehensive Utilization of Waste Power Batteries for New Energy Vehicles," which will take effect on April 1, 2026, mandating a full lifecycle management approach for retired batteries [4][16][17] - The total amount of retired lithium batteries in mainland China is projected to increase from 157,100 tons in 2020 to 455,100 tons in 2024, representing a compound annual growth rate (CAGR) of 30.5% [4][37][39] - The report identifies four companies listed on the Beijing Stock Exchange involved in lithium battery recycling, with a total market capitalization of 10.459 billion yuan as of January 23, 2026 [4][45][46] Group 2 - The chemical new materials sector experienced an average weekly increase of 5.11% in stock prices, with notable companies such as Meibang Technology and Tianli Composite showing significant gains [5][62] - The average price-to-earnings (P/E) ratio for the chemical new materials industry rose to 42.5X, indicating a positive market sentiment [5][62] - The technology sector saw a median P/E ratio increase from 44.3X to 44.7X, with a total market capitalization growth from 546.417 billion yuan to 560.692 billion yuan [6][76][77] Group 3 - The report emphasizes the importance of both tiered utilization and recycling of retired power batteries, with tiered utilization focusing on reusing batteries with remaining capacity for applications such as energy storage systems [25][26] - The recycling process aims to extract valuable materials from waste batteries, with physical and chemical recovery methods being the primary techniques employed [27][29][30] - The report notes that the global processing volume of retired batteries is expected to grow from 338,400 tons in 2020 to 1.3 million tons by 2024, with a CAGR of 40.6% [40]

Core Viewpoint - The OTC channel presents significant opportunities for beauty brands, offering professional endorsements, precise targeting of skincare needs, and immediate product experiences, but it also poses challenges due to strict professional requirements and a talent shortage in the industry [1][2][3]. Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, marking it as the "Year of Domestic Beauty OTC Layout" [2]. - Leading domestic beauty brand Proya (603605.SH) announced its entry into the OTC channel in January 2026, joining a growing list of companies [2]. - Brands like Winona and Kefu Beauty have been early entrants into the OTC channel, with Winona's sales nearing 1 billion yuan in 2023, capturing over 60% of the market share in this channel [5]. Group 2: Strategic Developments - In April 2025, Furuida Bio announced plans to accelerate its OTC channel development, aiming to cover 10,000 drugstore chains and launch 100 "cosmetic and medicinal" SKUs [5]. - Companies are increasingly focusing on integrating with the professional environment of pharmacies rather than merely distributing products [5]. - Proya is preparing multiple products for the OTC channel, emphasizing the importance of medical device products as a foundation for entry [6]. Group 3: Market Potential and Challenges - The OTC channel has approximately double the growth potential, with Winona targeting to cover 250,000 pharmacies [8]. - As of December 2024, there are about 705,000 licensed drug retail enterprises in China, with Winona covering over 110,000, representing about one-seventh of the total retail pharmacy stores [9]. - The demand for beauty products in pharmacies is rising due to pressures on traditional pharmacy profits and the need for transformation [9]. Group 4: Profitability and Talent Shortage - Medical device products have a significantly higher gross margin, averaging 77%-83%, compared to regular cosmetic products [9]. - The beauty industry faces a talent shortage in the pharmacy channel, as many brands rely on pharmacists who must understand both pharmaceuticals and cosmetics [10]. - Companies like Betaini are addressing this by training pharmacy staff to enhance customer trust and provide professional consultations [10][11].

Core Insights - The report highlights a decrease in the market value of public funds heavily invested in the Beijing Stock Exchange (BSE), which reached 9.05 billion yuan as of Q4 2025, a decline of 12.19% quarter-on-quarter [2] - The report indicates that the decline is primarily due to profit-taking by investors in thematic funds, with a total redemption of 1.48 billion units, accounting for 52% of the total units before redemption [2][17] - The average net value growth rate of thematic funds in 2025 was 56.7%, significantly outperforming the BSE 50 index's growth of 38.8% [17] Public Fund Investment Trends - As of Q4 2025, the market value of public funds invested in the BSE accounted for 0.27% of the total A-share market, a decrease of 0.04 percentage points [3][4] - The report notes that passive investment trends are ongoing, with index funds experiencing net subscriptions for three consecutive quarters, totaling 12.838 billion yuan as of Q4 2025, an increase of 7.55 billion yuan [2][13] - The report anticipates continued institutional investment in the BSE, with eight thematic funds pending market entry, including six index funds and two actively managed funds [2] Active Equity Fund Strategies - Active equity public funds are focusing on low-valuation growth stocks, with the valuation center of the top 10 stocks held by these funds dropping to 39 times earnings, below the valuation center of the BSE A-shares [2][20] - Key stocks of interest include Litong Technology (solid-state battery), Tongli Co. (lowest valuation on the BSE), and Lin Tai New Materials (low-valuation high-performance) [2][22] - The report also notes an increased focus on cyclical manufacturing sectors, such as basic chemicals and machinery, while reducing exposure to consumer sectors like beauty care and agriculture [2] Thematic Fund Performance - The report emphasizes that thematic funds have shown significant excess returns, with the average net value growth rate of thematic funds in 2025 being 56.7%, compared to the BSE 50's growth of 38.8% [17] - Specific funds that performed well include the "Hua Xia BSE Innovation Small and Medium Enterprises Selected Two-Year Open Fund," which had the lowest redemption ratio [2][15] - The report identifies a trend of active equity public funds increasing their holdings in stocks like Litong Technology, Tongli Co., and Lin Tai New Materials, indicating a strategic shift towards promising sectors [22]

Core Insights - The article discusses how certain industries are thriving despite a general perception of economic downturn, highlighting eight key sectors that present significant business opportunities [3][4]. Group 1: Key Industries - **Second-Hand Economy**: The second-hand luxury market in Japan, represented by companies like Daikokuya, has seen a surge in revenue. In China, platforms like Hongbulin and Panghu are experiencing similar growth [6][7][8]. - **Pet Economy**: With a decline in birth rates, spending on pets has increased, with brands like Inaba in Japan and Guobao (Zhongchong) in China seeing strong stock performance [12][13][14]. - **Adult Care**: The adult diaper market in Japan has surpassed $10 billion, indicating that aging populations can drive significant economic opportunities [17][18][19]. - **Health Food and Beverages**: Changes in population structure and rising health awareness have led to the growth of sugar-free products and functional beverages in both Japan and China [21][22]. - **Beauty Economy**: The demand for beauty products, such as collagen supplements and home beauty devices, remains strong, with brands like Weimei and U like achieving significant sales [23][24][25][26]. - **Outdoor Recreation**: Companies in the outdoor equipment sector, like Snow Peak in Japan, are capitalizing on the trend of outdoor activities, with Chinese brands also seeing rapid sales growth [29][31][32]. - **Convenience Economy**: The rise of frozen foods and smart home appliances reflects a shift towards convenience, with brands like Anjijia and Stone achieving steady growth [39][40]. - **Lazy Economy**: The trend of reduced cooking time among younger generations has led to increased demand for time-saving products, emphasizing the value of time over money in a low-desire economy [42][43]. Group 2: Market Trends - The article emphasizes that even in a low-desire society, there are substantial opportunities for those willing to invest in counter-cyclical sectors [44]. - The narrative suggests that the current economic climate should not deter investment but rather encourage a focus on emerging trends and consumer needs [44].

Core Insights - The article discusses the growing trend of domestic beauty brands entering the OTC (over-the-counter) channel in China, with 2025 being marked as a pivotal year for this transition [2][3] - Major players like Proya and other beauty companies are preparing to launch products in the OTC space, which is seen as a way to leverage the professional credibility of pharmacies and meet specific skincare needs [4][5] Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, expanding the current limited presence of leading brands [2] - Proya announced its entry into the OTC channel in January 2026, joining other brands that have already established a presence [2][4] - The OTC channel has seen significant sales, with brands like Winona achieving nearly 1 billion yuan in sales from this channel in 2023 [3] Group 2: Strategic Partnerships and Product Development - Companies are focusing on strategic partnerships and product development tailored for the OTC market, with Proya preparing multiple products aimed at post-operative recovery and daily skincare [4] - Winona and other brands are actively seeking to enhance their product offerings and market reach through collaborations with pharmacies [3][4] Group 3: Market Potential and Challenges - The OTC channel is projected to have about double the growth potential, with Winona aiming to cover 250,000 pharmacies [5] - The regulatory environment is becoming more favorable for pharmacies to sell cosmetic products, which aligns with the increasing demand for beauty products in these settings [6] - Despite the opportunities, there is a significant talent shortage in the OTC channel, as brands require personnel who are knowledgeable in both pharmaceuticals and cosmetics [7] Group 4: Financial Metrics and Profitability - The average gross margin for medical beauty products in the OTC channel is significantly higher than that of regular cosmetic products, with margins for medical dressings ranging from 77% to 83% [6] - Specific companies report high gross margins, such as 84.22% for Chuerjia's medical device products and 82% for Jinjian Biological's collagen products [6]